Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)
Status:
Terminated
Trial end date:
2017-11-01
Target enrollment:
Participant gender:
Summary
Dipyridamole, a medication extensively used in combination with aspirin for stroke
prevention, is a promising new treatment for lupus. Dipyridamole has been shown to inhibit
certain lymphocyte populations that are over-reactive in lupus and to delay the emergence of
lupus-related pathology in mice with lupus. The investigators are interested in investigating
the efficacy of dipyridamole in preventing flares in patients with lupus and its impact on
biomarkers of disease activity.